- Sepideh Izadi, .et al. Codelivery of HIF-1α siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression, Pharm Res, 2020, Sep 17;37(10):196 PMID: 32944844
- Shahin Hallaj, .et al. Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib, Life Sci, 2020, Jul 26 PMID: 32726663
- Washio I, .et al. Impact of Breast Cancer Resistance Protein Expression on the In Vitro Efficacy of Anticancer Drugs in Pancreatic Cancer Cell Lines, Drug Metab Dispos, 2018, Mar;46(3):214-222 PMID: 29246888
Biological Activity
Dinaciclib (SCH 727965) is a potent and selective cyclin-dependent kinase (CDK) inhibitor, selectively inhibiting CDK1, CDK2, CDK5 and CDK9 with IC50 values of 3, 1, 1 and 4 nM respectively.
Targets
CDK2 (Cell-free assay) | CDK5 (Cell-free assay) | CDK1 (Cell-free assay) | CDK9 (Cell-free assay) | |
1 nM | 1 nM | 3 nM | 4 nM |
In vitro (25°C) | DMSO | 26 mg/mL heating (65.57 mM) | |
Water | <1 mg/mL (<1 mM) | ||
Ethanol | 8 mg/mL heating (20.17 mM) | ||
In vivo | 15% Captisol | 6 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 25.22 mL | 126.1 mL | 252.21 mL |
0.5 mM | 5.04 mL | 25.22 mL | 50.44 mL |
1 mM | 2.52 mL | 12.61 mL | 25.22 mL |
5 mM | 0.5 mL | 2.52 mL | 5.04 mL |
*The above data is based on the productmolecular weight 396.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Catalog Num | A11129 |
---|---|
Actions | Inhibitor |
M. Wt | 396.5 |
Formula | C21H28N6O2 |
Solubility | DMSO |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 779353-01-4 |
Synonyms | SCH727965, SCH-727965 |
SMILES | CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[[email protected]]4CCO |
Datasheet
Product Tags
Product Questions
Product Questions
No Questions
You may also be interested in the following product(s)
PD 0332991 HCl (Palbociclib)
PD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activit…
AT7519 HCl
AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhib…
NVP-LCQ195
NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.
BS-181 HCl
BS-181 HCl is a potential anti-tumor agent as CDK7 inhibitor.
P276-00
P276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. In Phase 2/3
R547
R547 is a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs) (Ki = 1, 3, and 1 nM for CDK1, CDK2, …
CVT-313
CVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 2…
PHA-793887
PHA-793887, a novel potent inhibitor of Cdk, target on kinds of cyclin-dependent kinase under low concentrations and poses high activity ag…
Keywords:buy Dinaciclib (SCH 727965) | Dinaciclib (SCH 727965) Supplier | purchase | cost | manufacturer | order | distributor | buy 779353-01-4| 779353-01-4 Supplier | purchase 779353-01-4 | 779353-01-4 cost | 779353-01-4 manufacturer | order 779353-01-4 | 779353-01-4 distributor